Key result
Beta-blockers remain the cornerstone of therapy for CPVT, with flecainide, left cardiac sympathetic denervation, and ICDs serving as additive or alternative options for refractory cases.
Why the study?
The review aims to summarize the arrhythmogenic mechanisms, current therapeutic management, and potential future perspectives for catecholaminergic polymorphic ventricular tachycardia.
Answers are grounded in this paper and cite their sources.
This review highlights that while beta-blockers are the primary treatment for CPVT, flecainide and left cardiac sympathetic denervation are important adjunctive therapies, and ICDs must be used with extreme caution to avoid shock-induced electrical storms.
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a primary electrical disease characterized by a normal resting electrocardiogram and induction of malignant arrhythmias during adrenergic stress leading to syncope or sudden cardiac death (SCD). CPVT is caused by mutations in the cardiac ryanodine receptor (RyR2) or in the sarcoplasmic reticulum protein calsequestrin 2 genes (CASQ2). The RyR2 mutations are responsible for the autosomal dominant form of CPVT, while CASQ2 mutations are rare and account for the recessive form. These mutations cause a substantial inballance in the homeostasis of intracellular calcium resulting in polymorphic ventricular tachycardia through triggered activity. Beta blockers were for years the cornerstone of therapy in these patients. Sodium channel blockers, especially flecainide, have an additive role in those not responding in beta blockade. Implantation of defibrillators needs a meticulous evaluation since inappropriate shocks may lead to electrical storm. Finally, cardiac sympathetic denervation might also be an alternative therapeutic option. Early identification and risk stratification is of major importance in patients with CPVT. The aim of the present review is to present the arrhythmogenic mechanisms of the disease, the current therapies applied and potential future perspectives.
No takes yet. Share an insight, caveat, or question.
Baltogiannis et al. (2019) conducted a review in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Therapeutic management (Beta blockers, Flecainide, LCSD, ICD) was evaluated. Beta-blockers remain the cornerstone of therapy for CPVT, with flecainide, left cardiac sympathetic denervation, and ICDs serving as additive or alternative options for refractory cases.
Synapse has enriched 10 related papers. Consider them for comparative context: